• Albert Dirisamer, Benjamin S Halpern, Daniel Flöry, Florian Wolf, Mohsen Beheshti, Marius E Mayerhoefer, and Werner Langsteger.
• Department of Nuclear Medicine, St. Vincent's Hospital, Seilerstaette 4, 4010 Linz, Austria. albert.dirisamer@meduniwien.ac.at
• Eur J Radiol. 2010 Feb 1; 73 (2): 324-8.

ObjectiveThe purpose of this study was to assess the diagnostic value of PET/CT as a one step examination in patients with colorectal cancer. Therefore we proved whether diagnostic PET/CT adds information over PET or contrast-enhanced CT alone for staging or restaging of patients with colorectal cancer.MethodsSeventy-three patients (46 males and 27 females; age range: 50-81 years; mean age: 67 years) with known colorectal cancer underwent 18F-FDG-PET/CT for staging or restaging.ResultsOf the 73 patients 26 patients underwent PET/CT for staging and 47 for restaging. 266 metastases could be detected in 60 patients. Contrast-enhanced PET/CT had a lesion-based sensitivity of 100%, contrast-enhanced CT of 91% and PET of 85%. PET/CT identified 2 lesions as false positive. PET/CT could also reach a patient-based sensitivity of 100%, which was superior to contrast-enhanced CT and PET.ConclusionOur study clearly demonstrated the added value of contrast-enhanced PET/CT in staging and restaging patients with colorectal cancer over CT and PET alone.Copyright (c) 2008 Elsevier Ireland Ltd. All rights reserved.

23 keywords...

hide…